Sidley represented Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class bio therapeutics, in its collaboration with Sino Biopharma to develop two products enabled by Ambrx’s proprietary non-natural amino acid incorporation technology platforms.
Under the terms of the agreement, Ambrx received an upfront payment to create two innovative drug candidates, with Sino Biopharma leading Investigational New Drug application activities for both China and the U.S. The parties will jointly develop the programs to world-class standards with Sino Biopharma commercializing the products within the greater China area and Ambrx commercializing the products worldwide. Ambrx is eligible to receive additional milestone payments for development, regulatory, and sales-based events, as well as tiered royalties on future sales.
The Sidley team was led by M&A partner Ruchun Ji (Shanghai/Beijing/Palo Alto) and Technology and IP Transactions partner Stephen Abreu (San Francisco).
